索拉非尼治疗的肝细胞癌:动态增强CT动脉肿瘤灌注作为生存的早期影像生物标志物
研究纳入36例肝细胞癌患者,在索拉非尼治疗前及治疗一周后行肝脏灌注CT,测量肿瘤及肝实质的动脉灌注与门静脉灌注。治疗前肿瘤动脉灌注与总生存率显著相关(HR 0.16,95%CI 0.02-0.84,p=0.03),肿瘤动脉灌注比值有相关趋势(HR 2.94,95%CI 0.94-7.88,p=0.06)。治疗前肿瘤动脉灌注>71.7mL/min/100mL及灌注比值≤1.1的患者总生存率更高。
要点
- 治疗前肿瘤动脉灌注>71.7mL/min/100mL者总生存率更高(log-rank p<0.01)。
- 肿瘤动脉灌注比值≤1.1者总生存率更高(log-rank p=0.03)。
- 治疗前肿瘤动脉灌注与总生存率独立相关(HR 0.16,95%CI 0.02-0.84,p=0.03)。
核心结论
- 肝脏灌注CT可提供预测索拉非尼治疗肝细胞癌患者总生存的早期影像生物标志物。
研究设计与样本
- 研究纳入36例肝细胞癌患者,在索拉非尼治疗前及治疗一周后行肝脏灌注CT,测量肿瘤及肝实质的动脉灌注与门静脉灌注,计算治疗后与治疗前灌注值的比值。
诊断标准与关键数值
- 治疗前肿瘤动脉灌注与总生存率显著相关:HR 0.16(95%CI 0.02-0.84),p=0.03。
- 肿瘤动脉灌注比值与总生存率有相关趋势:HR 2.94(95%CI 0.94-7.88),p=0.06。
- 治疗前肿瘤动脉灌注>71.7mL/min/100mL者总生存率更高(Kaplan-Meier法log-rank检验p<0.01)。
- 肿瘤动脉灌注比值≤1.1者总生存率更高(Kaplan-Meier法log-rank检验p=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether hepatic perfusion CT yields early imaging biomarkers predictive of the prognosis of hepatocellular carcinoma (HCC) patients treated with sorafenib.
METHODS: We evaluated 36 HCC patients who underwent hepatic perfusion CT before- and one week after sorafenib therapy. We measured arterial and portal perfusion in the hepatic tumor and liver parenchyma [(AP)(PP)tumor], [(AP)(PP)liver]. The perfusion ratio was calculated by dividing the post- by the pre-sorafenib value. The effect of each value on the overall survival rate was analyzed with the Cox proportional hazards model; statistically significant parameters were subjected to receiver operating characteristic analysis based on median survival after sorafenib administration to determine the overall survival rate with the Kaplan-Meier method.
RESULTS: Pre-APtumor was significantly associated with the overall survival rate (hazard ratio (HR) and 95% confidence interval (CI), 0.16 and 0.02-0.84, p=0.03). The APtumor ratio tended to be associated with the overall survival rate (HR and 95% CI, 2.94 and 0.94-7.88, p=0.06). The overall survival rate was higher in patients with pre-APtumor>71.7mL/min/100mL, and with APtumor ratio≦1.1 (p<0.01 and 0.03, respectively, in Kaplan-Meier method with log-rank).
CONCLUSION: Hepatic perfusion CT yields early imaging biomarkers for predicting overall survival in HCC patients treated with sorafenib.
引用
- Nakamura Y, Kawaoka T, Higaki T, et al. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival. Eur J Radiol. 2017. PMID: 29279169. doi:10.1016/j.ejrad.2017.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。